Pr Pedro Buc Calderon, from Toxicology and Cancer Biology Research Group (GTOX), Louvain Drug Research Institute, Université catholique de Louvain (UCL), Bruxelles, Belgium will highlight how to exploite cancer cell redox status to optimize cancer therapy.
This topic will be held on July 3, during the first day of the 12th International Conference on Oxidative Stress and Antioxidants.
According Pr Buc Calderon Research:
Cancer cells are particularly vulnerable to treatments impairing redox homeostasis. Reactive oxygen species (ROS) can indeed play an important role in the initiation and progression of cancer, and advanced stage tumors frequently exhibit high basal levels of ROS that stimulate cell proliferation and promote genetic instability. In addition, an inverse correlation between histological grade and antioxidant enzyme activities is frequently observed in human tumors, further supporting the existence of a redox dysregulation in cancer cells. This biochemical property can be exploited by using redox-modulating compounds, which represent an interesting approach to induce cancer cell death. Thus, we have developed a new strategy based on the use of pharmacologic concentrations of ascorbate and redox-active quinones.
To know more about Pr Buc Calderon's strategy, you can join attendees of the conference by register here.
More information: www.isanh.fr
Share this post
Please click here to purchase
